Key Facts Eli Lilly’s shares dropped more than 14% to around $639 as of about 2:25 p.m. EDT, marking what would be the company’s steepest single-day loss since a 29% decline on Aug. 8, 2000.

South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.

Eli Lilly, the pharmaceutical company behind GLP-1 injection Zepbound, is working to bring its weight loss drug to the market in pill form. In an Aug. 7 earnings call, Eli Lilly CEO David Ricks ...

Shares of Eli Lilly and Co. tumbled 12.8% in premarket trading Thursday, toward its biggest one-day selloff in 26 years, after the drug giant disclosed late-stage trial data for its oral weight ...

Drugmaker Eli Lilly says its oral, daily GLP-1 pill may offer similar weight loss results as weekly GLP-1 shots. Eli Lilly, the maker of Mounjaro and Zepbound, said Thursday that the company's new ...

Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo© Thomson Reuters ...

Eli Lilly will seek regulatory approval for its next-generation weight-loss pill by year-end, based on data that suggests it may not be as potent as injectable GLP-1 drugs on the market.

An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to pharmaceutical companies Pfizer and Eli Lilly.

Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival Novo Nordisk did on Tuesday, and are anxiously awaiting a full-year ...